Global Blood Therapeutics Garners $120,000,000 New Financing

  • Feed Type
  • Date
    8/12/2015
  • Company Name
    Global Blood Therapeutics
  • Mailing Address
    400 East Jamie Court South San Francisco, CA 94080 USA
  • Company Description
    Global Blood Therapeutics, Inc. (NASDAQ: GBT) is a product-focused company building a pipeline of innovative, oral medicines to revolutionize the treatment of chronic blood-based diseases and severe genetic disorders for which there are currently no cures available and only extremely limited therapeutic options.
  • Website
    http://www.globalbloodtx.com
  • Transaction Type
    IPO
  • Transaction Amount
    $120,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    We intend to use the net proceeds from this offering and our cash and cash equivalents on hand as follows: approximately $50.0 million to fund our development of GBT440 for the treatment of SCD, including the completion of our ongoing Phase 1/2 clinical trial, planned clinical pharmacology studies and through the initiation of a pivotal clinical trial; approximately $15.0 million to conduct clinical trials of GBT440 or its analogs for the treatment of hypoxemic pulmonary disorders; approximately $15.0 million to complete and file an IND and begin a Phase 1/2 clinical trial of an oral kallikrein inhibitor for the treatment of HAE; and the remaining proceeds, if any, to fund new and ongoing research and development activities, working capital and other general corporate purposes, which may include funding for the hiring of additional personnel, capital expenditures and the costs of operating as a public company. Based on our current plans, we believe our cash and cash equivalents, togeth
  • M&A Terms

Trending on Xconomy